Patent Term Extension Application for BEQVEZ® (fidanacogene elaparvovec-dzkt), Patent No. 10,799,566
🏛 Food and Drug Administration (FDA)FDA-2024-E-3539
Documents
1
Total comments
1
all analyzed
Comment status
Open
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
📄 Primary document
NoticeFeb 6, 2026
Determination of Regulatory Review Period for Purposes of Patent Extension; BEQVEZClosing soon · 5 days left💬 1 comment